Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
Maria Pallozzi, Natalia Di Tommaso, Valeria Maccauro, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4631-4631
Open Access | Times Cited: 20

Showing 20 citing articles:

Biomarkers for immunotherapy of hepatocellular carcinoma
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 780-798
Closed Access | Times Cited: 92
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Maria Eva Argenziano, Mi Na Kim, Michele Montori, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 922-940
Closed Access | Times Cited: 6
Role of Gut Microbial Metabolites in the Pathogenesis of Primary Liver Cancers
Maria Pallozzi, Valeria De Gaetano, Natalia Di Tommaso, et al.
Nutrients (2024) Vol. 16, Iss. 14, pp. 2372-2372
Open Access | Times Cited: 5
Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
E. Pinto, Paola Meneghel, Fabio Farinati, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 4, pp. 579-588
Open Access | Times Cited: 14
Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
Ludovico Abenavoli, Michele Montori, Gianluca Svegliati‐Baroni, et al.
Medicina (2023) Vol. 59, Iss. 8, pp. 1427-1427
Open Access | Times Cited: 13
Advances in Histological and Molecular Classification of Hepatocellular Carcinoma
Joon Hyuk Choi, Swan N. Thung
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2582-2582
Open Access | Times Cited: 12
Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma
Zhiqiang Liu, Lingge Yang, Chun Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
Shuqun Li, Junyi Wu, Jiayi Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Ran Qin, Tianqiang Jin, Feng Xu
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Dendritic cell-derived exosome (DEX) therapy for digestive system cancers: Recent advances and future prospect
Sulieman Ibraheem Shelash Al-Hawary, Yasir Q. Аlmajidi, Pooja Bansal, et al.
Pathology - Research and Practice (2024) Vol. 257, pp. 155288-155288
Closed Access | Times Cited: 1
The upregulation of CLGN in hepatocellular carcinoma is potentially regulated by hsa-miR-194-3p and associated with patient progression
Zhongyuan Cui, Jielong Wang, Gang Chen, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 2
A novel tumor 4-driver gene signature for the prognosis of hepatocellular carcinoma
Houtian Guo, Fei Lu, Rongqi Lu, et al.
Heliyon (2023) Vol. 9, Iss. 6, pp. e17054-e17054
Open Access | Times Cited: 2
Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation
Jordi Yang Zhou, Dominik Eder, Florian Weber, et al.
Frontiers in Transplantation (2023) Vol. 2
Open Access | Times Cited: 2
Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma
Chuanlei Wang, Wei Feng, Xiaodong Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Deciphering the Multifaceted Immune Landscape of Unresectable Primary Liver Cancer to Predict Immunotherapy Response
Jun Xue, S. Yang, Si‐Si Zhang, et al.
Advanced Science (2024)
Open Access
The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma
Qu Xie, Can Hu, Cong Luo
Journal of Cancer (2023) Vol. 14, Iss. 15, pp. 2946-2955
Open Access | Times Cited: 1
Machine learning and biomarkers in hepatocellular carcinoma: The future is now
Francesca Romana Ponziani, Edoardo G. Giannini, Quirino Lai
Liver Cancer International (2022) Vol. 3, Iss. 3, pp. 111-112
Open Access | Times Cited: 2
Predictive Value of Peripheral Blood Markers in Hepatocellular Carcinoma Patients Treated with Anti-PD-1 in Combination with Targeted Therapy
Shaodong Wang, Chengyou Du
Journal of Cancer Therapy (2023) Vol. 14, Iss. 04, pp. 127-138
Open Access
Three molecular subtypes and a five‐gene signature for hepatocellular carcinoma based on m7G‐related classification
Yuan Yue, Jie Tao, Dan An, et al.
The Journal of Gene Medicine (2023) Vol. 26, Iss. 1
Closed Access
Page 1

Scroll to top